Nasdaq · CIK 0001808805
NAUT Nautilus Biotechnology, Inc.
Insider trading from SEC Form 4. Last filing Sep 9, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
9
with a Form 4 at this company
Signals
Open-market buys and sells at Nautilus Biotechnology, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 44Moderate | Sujal M Patel CEO, President, and Secretary buy | $136k 200,000 shares | +2% | - | |
| 29Weak | Matthew B. Murphy General Counsel buy | $13k 20,000 shares | +37% | - | |
| 28Weak | Anna Mowry CFO and Treasurer buy | $11k 15,000 shares | +22% | - | |
| 10Weak | Parag Mallick Chief Scientist buy | $9,885 13,500 shares | +0% | - |
Transactions
The last 11 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 5, 2025 | Sujal M Patel CEO, President, and Secretary | POpen-market purchase Common Stock | +116,500 | $0.67 | $79k | 10,258,221 | Sep 9, 2025 |
| Sep 8, 2025 | Sujal M Patel CEO, President, and Secretary | POpen-market purchase Common Stock | +83,500 | $0.68 | $57k | 10,341,721 | Sep 9, 2025 |
| Sep 4, 2025 | Matthew B. Murphy General Counsel | POpen-market purchase Common Stockindirect: See Footnote | +20,000 | $0.64 | $13k | 74,140 | Sep 5, 2025 |
| Jun 23, 2025 | Karen Akinsanya director | AGrant or award Stock Option (Right to Buy)derivative | +45,000 | $0.00 | $0 | 45,000 | Jun 25, 2025 |
| Jun 23, 2025 | Epperly Melissa B director | AGrant or award Stock Option (Right to Buy)derivative | +45,000 | $0.00 | $0 | 45,000 | Jun 25, 2025 |
| Jun 23, 2025 | Matthew S McIlwain director | AGrant or award Stock Option (Right to Buy)derivative | +45,000 | $0.00 | $0 | 45,000 | Jun 25, 2025 |
| Jun 23, 2025 | Farzad Nazem director | AGrant or award Stock Option (Right to Buy)derivative | +45,000 | $0.00 | $0 | 45,000 | Jun 25, 2025 |
| Jun 23, 2025 | Matthew L. Posard director | AGrant or award Stock Option (Right to Buy)derivative | +45,000 | $0.00 | $0 | 45,000 | Jun 25, 2025 |
| May 29, 2025 | Anna Mowry CFO and Treasurer | POpen-market purchase Common Stock | +15,000 | $0.77 | $11k | 83,000 | Jun 2, 2025 |
| May 8, 2025 | Parag Mallick Chief Scientist | POpen-market purchase Common Stock | +12,000 | $0.73 | $8,788 | 20,491,892 | May 12, 2025 |
| May 12, 2025 | Parag Mallick Chief Scientist | POpen-market purchase Common Stock | +1,500 | $0.73 | $1,098 | 20,493,392 | May 12, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Karen Akinsanyapresident, officer, director
- Epperly Melissa Bdirector
- Parag MallickChief Scientist
- Matthew S McIlwaindirector
- Anna MowryCFO and Treasurer
- Matthew B. MurphyGeneral Counsel
- Farzad Nazemdirector
- Sujal M PatelCEO, President, and Secretary
- Matthew L. Posarddirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.